Platelets in Non-alcoholic Fatty Liver Disease
Non alcoholic steatohepatitis (NASH) is the inflammatory reaction of the liver to excessive accumulation of lipids in the hepatocytes. NASH can progress to cirrhosis and hepatocellular carcinoma (HCC). Fatty liver is the hepatic manifestation of metabolic syndrome. A subclinical inflammatory state i...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.842636/full |
| _version_ | 1818293957064392704 |
|---|---|
| author | Andrea Dalbeni Andrea Dalbeni Marco Castelli Mirko Zoncapè Mirko Zoncapè Pietro Minuz David Sacerdoti |
| author_facet | Andrea Dalbeni Andrea Dalbeni Marco Castelli Mirko Zoncapè Mirko Zoncapè Pietro Minuz David Sacerdoti |
| author_sort | Andrea Dalbeni |
| collection | DOAJ |
| description | Non alcoholic steatohepatitis (NASH) is the inflammatory reaction of the liver to excessive accumulation of lipids in the hepatocytes. NASH can progress to cirrhosis and hepatocellular carcinoma (HCC). Fatty liver is the hepatic manifestation of metabolic syndrome. A subclinical inflammatory state is present in patients with metabolic alterations like insulin resistance, type-2 diabetes, obesity, hyperlipidemia, and hypertension. Platelets participate in immune cells recruitment and cytokines-induced liver damage. It is hypothesized that lipid toxicity cause accumulation of platelets in the liver, platelet adhesion and activation, which primes the immunoinflammatory reaction and activation of stellate cells. Recent data suggest that antiplatelet drugs may interrupt this cascade and prevent/improve NASH. They may also improve some metabolic alterations. The pathophysiology of inflammatory liver disease and the implication of platelets are discussed in details. |
| first_indexed | 2024-12-13T03:24:06Z |
| format | Article |
| id | doaj.art-f90ce9dbff9643519bec47f74e5e9b3b |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-13T03:24:06Z |
| publishDate | 2022-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-f90ce9dbff9643519bec47f74e5e9b3b2022-12-22T00:01:18ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-02-011310.3389/fphar.2022.842636842636Platelets in Non-alcoholic Fatty Liver DiseaseAndrea Dalbeni0Andrea Dalbeni1Marco Castelli2Mirko Zoncapè3Mirko Zoncapè4Pietro Minuz5David Sacerdoti6Division of General Medicine C, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, ItalyLiver Unit, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, ItalyDivision of General Medicine C, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, ItalyDivision of General Medicine C, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, ItalyLiver Unit, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, ItalyDivision of General Medicine C, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, ItalyLiver Unit, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, ItalyNon alcoholic steatohepatitis (NASH) is the inflammatory reaction of the liver to excessive accumulation of lipids in the hepatocytes. NASH can progress to cirrhosis and hepatocellular carcinoma (HCC). Fatty liver is the hepatic manifestation of metabolic syndrome. A subclinical inflammatory state is present in patients with metabolic alterations like insulin resistance, type-2 diabetes, obesity, hyperlipidemia, and hypertension. Platelets participate in immune cells recruitment and cytokines-induced liver damage. It is hypothesized that lipid toxicity cause accumulation of platelets in the liver, platelet adhesion and activation, which primes the immunoinflammatory reaction and activation of stellate cells. Recent data suggest that antiplatelet drugs may interrupt this cascade and prevent/improve NASH. They may also improve some metabolic alterations. The pathophysiology of inflammatory liver disease and the implication of platelets are discussed in details.https://www.frontiersin.org/articles/10.3389/fphar.2022.842636/fullnon-alcoholic fatty liver diseasenon-alcoholic steatohepatitisinflammationfibrosisplateletsKupffer cells |
| spellingShingle | Andrea Dalbeni Andrea Dalbeni Marco Castelli Mirko Zoncapè Mirko Zoncapè Pietro Minuz David Sacerdoti Platelets in Non-alcoholic Fatty Liver Disease Frontiers in Pharmacology non-alcoholic fatty liver disease non-alcoholic steatohepatitis inflammation fibrosis platelets Kupffer cells |
| title | Platelets in Non-alcoholic Fatty Liver Disease |
| title_full | Platelets in Non-alcoholic Fatty Liver Disease |
| title_fullStr | Platelets in Non-alcoholic Fatty Liver Disease |
| title_full_unstemmed | Platelets in Non-alcoholic Fatty Liver Disease |
| title_short | Platelets in Non-alcoholic Fatty Liver Disease |
| title_sort | platelets in non alcoholic fatty liver disease |
| topic | non-alcoholic fatty liver disease non-alcoholic steatohepatitis inflammation fibrosis platelets Kupffer cells |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.842636/full |
| work_keys_str_mv | AT andreadalbeni plateletsinnonalcoholicfattyliverdisease AT andreadalbeni plateletsinnonalcoholicfattyliverdisease AT marcocastelli plateletsinnonalcoholicfattyliverdisease AT mirkozoncape plateletsinnonalcoholicfattyliverdisease AT mirkozoncape plateletsinnonalcoholicfattyliverdisease AT pietrominuz plateletsinnonalcoholicfattyliverdisease AT davidsacerdoti plateletsinnonalcoholicfattyliverdisease |